



## Metal-Based Prodrugs and Nanoparticles in Cancer Therapy

Guest Editors:

**Dr. Irina Naletova**

**Prof. Dr. Barbara Tomasello**

**Dr. Victor V. Pleshkan**

Deadline for manuscript  
submissions:

**closed (10 August 2023)**

### Message from the Guest Editors

Transition metal complexes have long been used to treat cancer but many concerns are responsible for the current stall in the field of metal anticancer drugs. Nowadays, one of the strategies is to convert them into inert prodrugs, so that they can travel to the tumour site unchanged and release the drug in its active form only there. Moreover, the development of novel nanodrug delivery systems have been attracting growing interests as allow to improve pharmacokinetic and pharmacodynamic properties and show more therapeutic efficacy and less potential toxicity.

This Special Issue welcomes contributions dealing with synthetic methods for the realization of novel metallo-prodrugs, nanosystems and/or metaldrug in nanoparticles; analysis of pharmacokinetic and pharmacodynamic properties of metal-based prodrugs, chemotherapeutics or metal drugs encapsulated in nanostructures; in vitro or in vivo evaluation of therapeutic properties of metal-based prodrugs, nanoparticles and nanostructured materials functionalized with therapeutic metal complexes; Use of metal-pro drugs or/and nanoparticles in diagnosis, medical imaging, therapy and theranostics as well.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

Pharmaceutics Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma